BONFANTI PAOLO

Snyder, T., Gittelman, R., Klinger, M., May, D., Osborne, E., Taniguchi, R., et al. (2025). Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levels. FRONTIERS IN IMMUNOLOGY, 15 [10.3389/fimmu.2024.1488860]. Detail

De Vito, A., Tavelli, A., Cozzi-Lepri, A., Giacomelli, A., Rossotti, R., Ponta, G., et al. (2025). Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort. HIV MEDICINE [10.1111/hiv.70037]. Detail

Gagliardini, R., Giacomelli, A., Mussini, C., Cole, S., Edwards, J., Pinnetti, C., et al. (2025). Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: a trial emulation. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 155(June 2025) [10.1016/j.ijid.2025.107883]. Detail

Ripamonti, D., Comi, L., Francavilla, A., Valenti, D., Cossu, M., Moschese, D., et al. (2025). Long-term durability of dolutegravir plus darunavir/cobicistat dual regimen in highly antiretroviral-experienced people with HIV (DoDaco study). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY [10.1093/jac/dkaf119]. Detail

Socio, G., Ricci, E., Piconi, S., Squillace, N., Maggi, P., Orofino, G., et al. (2025). Impact of smoking habits on cardiovascular and neoplastic events and all-cause death in people living with HIVfrom the STOPSHIV cohort. AIDS, 39(2 (February 01, 2025)), 143-152 [10.1097/QAD.0000000000004042]. Detail